H.C. Wainwright analyst Andres Maldonado raised the firm’s price target on Palvella Therapeutics (PVLA) to $75 from $38 and keeps a Buy rating on the shares. The firm cites the company’s progress towards a Qtorin Rapamycin launch and positive key opinion leader sentiment as a “pipeline-in-a-product” for the target increase. It continues to believes Qtorin could become first line therapy for microcystic lymphatic malformations and cutaneous venous malformations.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Palvella Therapeutics Advances Rare Disease Pipeline
- Palvella Therapeutics price target raised to $60 from $50 at Chardan
- Palvella Therapeutics: Strong Financial Position and Clinical Progress Justify Buy Rating with Raised Price Target
- Positive Buy Rating for Palvella Therapeutics Driven by Promising Phase 3 Trial Developments and Market Potential
- Palvella Therapeutics price target raised to $60 from $45 at Stifel